" class="no-js "lang="en-US"> TheraVet Optimizes its Commercial Strategy in France with a New Distribution Agreement with Elvetis - Medtech Alert
Tuesday, April 23, 2024

TheraVet Optimizes its Commercial Strategy in France with a New Distribution Agreement with Elvetis

TheraVet, a pioneering biotechnology company in the treatment of bone and joint diseases in pets, announces the signing of a new exclusive distribution agreement for its line of bone substitutes BIOCERA-VET® with Elvetis, one of the main specialists in animal health products in France. The whole range, namely BIOCERA-VET® Bone Surgery (BS) RTU, BIOCERA-VET® BS Granules, BIOCERA-VET® BS SmartGraft and BIOCERA-VET® Osteosarcoma, is covered by this agreement.

Elvetis is one of the French subsidiaries of the Neftys Pharma group, a distributor of veterinary products for 30 years, the French company puts its expertise every day at the service of more than 7,500 customers in France and several European countries, thanks to a diversified product portfolio and the know-how of its employees. Neftys Pharma is specializing in veterinary distribution which generates more than €450 million in turnover. The family business has asserted its international presence for several years, allowing it today to be among the leaders in veterinary distribution in Europe.

Through this agreement, TheraVet strengthens and optimizes its distribution strategy in France, which includes a direct approach for its network of very high-potential clinics and an indirect approach for the rest of the veterinary clinics based on a partner with a sales force in the field targeting its population of prescribers. TheraVet now has better leverage to market the BIOCERA-VET® line in the second largest companion animal market in Europe with a population of 22 million dogs and cats.

Enrico Bastianelli, Managing Director of TheraVet, comments: “This new agreement concluded with a quality partner of Elvetis will allow BIOCERA-VET® to benefit from a double leverage effect – direct and indirect – on the French market. It is a fine example of optimizing TheraVet’s commercial strategy: focus our own commercial forces on very high-potential prescribers and rely on solid distributors to maximize the penetration of our products.”

Nicolas LANG, Managing Director of NEFTYS PHARMA: “I am enthusiastic about the idea of ​​starting this ambitious collaboration with TheraVet and contributing to the French development of their innovative BIOCERA-VET® range. Theravet products represent a major advance in the surgical treatment of osteoarticular lesions in companion animals. Validated by specialist veterinarians, they offer a high level of quality in terms of both efficacy and safety. They are also easy to use.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more